These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Indications and efficacy of biologics in inflammatory arthritis]. Combe B Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014 [TBL] [Abstract][Full Text] [Related]
5. Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice? van Royen-Kerkhof A; Vastert BS; Swart JF; Wulffraat NM Immunotherapy; 2014; 6(1):1-3. PubMed ID: 24341875 [No Abstract] [Full Text] [Related]
6. [Rheumatoid arthritis: current status of therapy]. El Bahri DM; Meddeb N; Sellami S Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701 [TBL] [Abstract][Full Text] [Related]
7. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191 [TBL] [Abstract][Full Text] [Related]
8. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258 [TBL] [Abstract][Full Text] [Related]
9. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents. Bello SL; Serafino L; Bonali C; Terlizzi N; Fanizza C; Anecchino C; Lapaldula G Reumatismo; 2012 Dec; 64(5):299-306. PubMed ID: 23256105 [TBL] [Abstract][Full Text] [Related]
10. Serious infections associated with anticytokine therapies in the rheumatic diseases. Giles JT; Bathon JM J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118 [TBL] [Abstract][Full Text] [Related]
18. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666 [TBL] [Abstract][Full Text] [Related]
19. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740 [No Abstract] [Full Text] [Related]
20. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C; Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]